W L Gore and Associates (Gore) has enrolled the first US patient in its study for the assessment of its investigational Gore VIAFORT Vascular Stent to treat symptomatic iliofemoral venous obstruction.
The subject was enrolled by Dr David Dexter II at Sentara Vascular Specialists healthcare facility in Norfolk, Virginia.
Go deeper with GlobalData
The multi-centre, non-randomised, prospective single-arm study is being carried out in the US and comes with a five-year follow-up.
Dexter said: “With several FDA-approved stents on the market, there was a concern that enrolment in another iliac vein stent trial would be difficult.
“Designed with the unique qualities for flexibility and radial force, the VIAFORT Device is compelling to use in a clinical trial.”
See Also:
The clinical trial is focused on assessing the device in a 10mm to 20mm diameter treatment range for iliofemoral veins.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThe device leverages the Gore expanded polytetrafluoroethylene technology, along with a single-wire, sinusoidal-wound nitinol frame.
Founded in 1958, Gore is involved in the development of medical devices to treat various cardiovascular and other health conditions.
In February this year, Gore announced the start of its EMBRACE Registry to evaluate the safety and clinical performance of the VBX stent graft for use as a bridging stent with a branched/fenestrated stent graft to treat aortic aneurysms involving the renal-mesenteric arteries.
